FIG. 1A

CATCATCAATAATATACCTTATTTTGGATTGAAGCCAATATGATAATGAGGGGTGGAGTTT
GTGACGTGGCGCGGGGCGTGGGAACGGGGCGGGTGACGTAGTAGTGTGGCGGAAGTGTGATG
TTGCAAGTGTGGCGGAACACATGTAAGCGACGGATGTGGCAAAAGTGACGTTTTTGGTGTGC
GCCGGTGTACACAGGAAGTGACAATTTTCGCGCGGTTTTAGGCGGATGTTGTAGTAAATTTG
GGCGTAACCGAGTAAGATTTGGCCATTTTCGCGGGAAAACTGAATAAGAGGAAGTGAAATCT
GAATAATTTTGTGTTACTCATAGCGCGTAATATTTGTCTAGG-ACTGAAAATG (SEQ ID NO: 3)

FIG. 1B

CATCATCAATAATATACCTTATTTTGGATTGAAGCCAATATGATAATGAGGGGTGGAGTTT
GTGACGTGGCGCGGGGCGTGGGAACGGGGCGGGTGACGTAGTAGTGTGGCGGAAGTGTGATG
TTGCAAGTGTGGCGGAACACATGTAAGCGACGGATGTGGCAAAAGTGACGTTTTTGGTGTGC
GCCGGTGTACACAGGAAGTGACAATTTTCGCGCGGTTTTAGGCGGATGTTGTAGTAAATTTG
GGCGTAACCGAGTAAGATTTGGCCATTTTCGCGGGAAAACTGAATAAGAGGAAGTGAAATCT
GAATAATTTTGTGTTACTCATAGCGCGTAATATTTGTCTAGGGCCGCGGGGACTTTGACCGT
TTACGTGGAGACTCGCCCAGGTGTTTTTCTCAGGTGTTTTCCGCGTTCCGGGTCAAAGTTGG
CGTTTTATTATTATAGTCAGCTGACGTGTAGTG-CCCGGTGAGTTCCTCAAGAGGCCACTCT
TGAGTGCCAGCGAGTAGAGTTTTCTCCTCCGAGCCGCTCCGACACCGGGACTGAAAATG
(SEQ ID NO: 15)

FIG. 1C

CATCATCAATAATATACCTTATTTTGGATTGAAGCCAATATGATAATGAGGGGTGGAGTTT
GTGACGTGGCGCGGGGCGTGGGAACGGGGCGGGTGACGTAGTAGTGTGGCGGAAGTGTGATG
TTGCAAGTGTGGCGGAACACATGTAAGCGACGGATGTGGCAAAAGTGACGTTTTTGGTGTGC
GCCGGTGTACACAGGAAGTGACAATTTTCGCGCGGTTTTAGGCGGATGTTGTAGTAAATTTG
GGCGTAACCGAGTAAGATTTGGCCATTTTCGCGGGAAAACTGAATAAGAGGAAGTGAAATCT
GAATAATTTTGTGTTACTCATAGCGCGTAATATTTGTCTAGGGCCGCGGGGACTTTGACCGT
TTACGTGGAGACTCGCCCAGGTGTTTTTCTCAGGTGTTTTCCGCGTTCCG-TGGCGTTTTA
TTATTATAGTCAGCTGACGTGTAGTGTATTTATACCCGGTGAGTTCCTCAAGAGGCCACTCT
TGAGTGCCAGCGAGTAGAGTTTTCTCCTCCGAGCCGCTCCGACACCGGGACTGAAAATG
(SEQ ID NO: 16)

FIG. 1D

CATCATCAATAATATACCTTATTTTGGATTGAAGCCAATATGATAATGAGGGGTGGAGTTT
GTGACGTGGCGCGGGGCGTGGGAACGGGGCGGGTGACGTAGTAGTGTGGCGGAAGTGTGATG
TTGCAAGTGTGGCGGAACACATGTAAGCGACGGATGTGGCAAAAGTGACGTTTTTGGTGTGC
GCCGGTGTACACAGGAAGTGACAATTTTCGCGCGGTTTTAGGCGGATGTTGTAGTAAATTTG
GGCGTAACCGAGTAAGATTTGGCCATTTTCGCGGGAAAACTGAATAAGAGGAAGTGAAATCT
GAATAATTTTGTGTTACTCATAGCGCGTAATATTTGTCTAGGGCCGCGGGGACTTTGACCGT
TTACGTGGAGACTCGCCCAGGTGTTTTTCTCAGGTGTTTTCCGCGTTCCG-TGGCGTTTTA
TTATTATAGTCAGCTGACGTGTAGTG-CCCGGTGAGTTCCTCAAGAGGCCACTCTTGAGTGC
CAGCGAGTAGAGTTTTCTCCTCCGAGCCGCTCCGACACCGGGACTGAAAATG (SEQ ID NO: 17)

FIG. 1E

CATCATCAATAATATACCTTATTTTGGATTGAAGCCAATATGATAATGAGGGGGTGGAGTTT
GTGACGTGGCGCGGGGCGTGGGAACGGGGCGGGTGACGTAGTAGTGTGGCGGAAGTGTGATG
TTGCAAGTGTGGCGGAACACATGTAAGCGACGGATGTGGCAAAAGTGACGTTTTTGGTGTGC
GCCGGTGTACACAGGAAGTGACAATTTTCGCGCGGTTTTAGGCGGATGTTGTAGTAAATTTG
GGCGTAACCGAGTAAGATTTGGCCATTTTCGCGGGAAAACTGAATAAGAGGAAGTGAAATCT
GAATAATTTTGTGTTACTCATAGCGCGTAATATTTGTCTAGGGCCGCGGGGACTTTGACCGT
TTACGTGGAGACTCGCCCAGGTGTTTTTCTCAGGTGTTTTCCGCGTTCCG-TGGCGTTTTA
TTATTATAGTCAGCTGACGTGTAGTGTATT-CCCGGTGAGTTCCTCAAGAGGCCACTCTTGA
GTGCCAGCGAGTAGAGTTTTCTCCTCCGAGCCGCTCCGACACCGGGACTGAAAATG (SEQ ID NO: 26)

FIG. 1F

CATCATCAATAATATACCTTATTTTGGATTGAAGCCAATATGATAATGAGGGGGTGGAGTTT
GTGACGTGGCGCGGGGCGTGGGAACGGGGCGGGTGACGTAGTAGTGTGGCGGAAGTGTGATG
TTGCAAGTGTGGCGGAACACATGTAAGCGACGGATGTGGCAAAAGTGACGTTTTTGGTGTGC
GCCGGTGTACACAGGAAGTGACAATTTTCGCGCGGTTTTAGGCGGATGTTGTAGTAAATTTG
GGCGTAACCGAGTAAGATTTGGCCATTTTCGCGGGAAAACTGAATAAGAGGAAGTGAAATCT
GAATAATTTTGTGTTACTCATAGCGCGTAATATTTGTCTAGGGCCGCGGGGACTTTGACCGT
TTACGTGGAGACTCGCCCAGGTGTTTTTCTCAGGTGTTTTCCGCGTTCCGGGTCAAAGTTGG
CGTTTTATTATTATAGTCAGCTGACGTGTAGTGTATTTATACCCGGTGAGTTCCTCAAGAGG
CCACTCTTGAGTGCCAGCGAGTAGAGTTTTCTCCTCCGAGCCGCTCCGACACCGGGACTGAA
AATG (SEQ ID NO: 27)

FIG. 2A



Ad-TAV-255
Ad-Δ350
L
CN
24
48
72
24
48
72
E1A

FIG. 2B



Ad-Δ350
Ad-TAV-255
L
CN
24
48
72
24
48
72
E1A

FIG. 3A



M
CN
TAV-255 (3)
TAV-255 (5)
Δ350 (3)
Δ350 (5)

FIG. 3B



M
CN
TAV-255 (3)
TAV-255 (5)
Δ350 (3)
Δ350 (5)
E1A

FIG. 4A



MOI
HTC26
Panc1
A549
HTC
Panc1
A549
3
5
10
CN
Four Days
Five days

FIG. 4B



MRC5
MOI 3
WI38
MOI 5
Ad-TAV-255
Ad-Δ350
CN

FIG. 5




FIG. 6



Non-infected
Ad-TATA
Ad-CAAT
Ad-CAAT-TATA
Ad-Δ350
Ad-TAV-Δ19k
ADS-12
ASPC 1
HT-29
Hep 3b

FIG. 7



Non-infected
Ad-TATA
Ad-CAAT
Ad-CAAT-TATA
Ad-Δ350
Ad-TAV-Δ19k
ADS 12
ASPC-1
HT-29
Hep 3b

FIG. 8



Non-infected
Ad-TATA
Ad-CAAT
Ad-CAAT-TATA
Ad-Δ350
Ad-TAV-Δ19k
Panc 1
A549
MeWo
HCT-116

FIG. 9



Non-infected
Ad-TATA
Ad-CAAT
Ad-CAAT-TATA
Ad-Δ350
Ad-TAV-Δ19k
Panc 1
A549
MeWo
HCT-116

FIG. 10



Non-infected
Ad-CAAT
Ad-CAAT-TATA
Ad-TATA
Ad-Δ350
Ad-TAV-Δ19k
A549
HCT116
Hep3b
Panc1

FIG. 11



Non-infected
Ad-CAAT
Ad-CAAT-TATA
Ad-TATA
Ad-Δ350
Ad-TAV-Δ19k
MeWo
HT29
ADS12
ASPC

FIG. 12



Non-infected
Ad-TATA
Ad-CAAT
Ad-CAAT-TATA
Ad-Δ350
Ad-TAV-Δ19k
MOI 5
MOI 3

FIG. 13



Non-infected
Ad-TATA
Ad-CAAT
Ad-CAAT-TATA
Ad-Δ350
Ad-TAV-Δ19k
MOI 5
MOI 3

FIG. 14




FIG. 15




FIG. 16




FIG. 17




FIG. 18




FIG. 19




FIG. 20




FIG. 21




FIG. 22



1500
1250
1000
750
500
250
0
mGM-CSF concentration (ng/ml)
Ad-Δ350-Δ19K
Ad-Δ350-mGMCSF

FIG. 23



mGM-CSF production in ADS12 cells, 4 days post-infection
mGM-CSF concentration (ng/ml)
150
125
100
75
50
25
0
Ad-Δ350-Δ19K, 10 MOI
Ad-Δ350-mGMCSF, 5 MOI
Ad-Δ350-mGMCSF, 10 MOI

FIG. 24



Buffer
350-19k
TAV-19k
Tumor volume (mm³)
Day after start of treatment
0
50
100
150
200
250
300
10
20
30
40
60

FIG. 25

